LCTX
Lineage Cell Therapeutics, Inc.
There isn't enough reported data to score LCTX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LCTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
LCTX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCTX PE Valuation
LCTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LCTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LCTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$0.12 | +$0.01 |
| Q2 2024 | -$0.14 | -$0.01 |
| Q1 2024 | -$0.14 | $0.00 |
| Q4 2023 | -$0.13 | +$0.02 |
| Q3 2023 | -$0.13 | +$0.16 |
| Q2 2023 | -$0.13 | +$0.17 |
| Q1 2023 | -$0.14 | +$0.15 |
| Q4 2022 | -$0.15 | +$0.11 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 175% for LCTX versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LCTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | -61% |
| Q2 2026 | $1.1M | -61% |
| Q1 2026 | $1.7M | +15% |
| Q4 2025 | $6.6M | +130% |
| Q3 2025 | $3.7M | -2.6% |
| Q2 2025 | $2.8M | +96% |
| Q1 2025 | $1.5M | +4% |
| Q4 2024 | $2.9M | +37% |
LCTX's revenue has held roughly level: $1M last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -510% | -407 points |
| Q2 2026 | -835% | -119 points |
| Q1 2026 | -440% | -7.1 points |
| Q4 2025 | -99% | +79 points |
| Q3 2025 | -103% | -1.2 points |
| Q2 2025 | -715% | -299 points |
| Q1 2025 | -433% | +28 points |
| Q4 2024 | -178% | +127 points |
LCTX's operating margin was −510% last quarter, down 407 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LCTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LCTX on profitability, with a higher operating margin.
LCTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | -$2.1M |
| Q2 2026 | -$7.4M | -$1.8M |
| Q1 2026 | -$8.1M | -$3.2M |
| Q4 2025 | -$5.3M | +$1.4M |
| Q3 2025 | -$3.6M | +$2.3M |
| Q2 2025 | -$5.6M | -$327K |
| Q1 2025 | -$5M | +$838K |
| Q4 2024 | -$6.7M | -$601K |
LCTX has burned cash in almost every quarter: −$26M over the past year, against −$21M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LCTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -2.4M shares |
| 1 year | +13% | +30.2M shares |
| 3 years | +52% | +88.5M shares |
| 5 years | +73% | +109M shares |
LCTX has 259M diluted shares, up 13% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LCTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LCTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.1x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
LCTX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LCTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 39.4 | Neutral |
LCTX's weekly RSI is 40 (neutral) and its Stochastic is 39 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LCTX PE vs Healthcare Sector
LCTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LCTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 0% above |
| 20 week MA | $1.07 | 7.5% below |
| 50 week MA | $1.35 | 27% below |
| 100 week MA | $1.16 | 15% below |
| 200 week MA | $1.15 | 14% below |
LCTX is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LCTX on trend strength, trading above more of its moving averages.
LCTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.77 | $1.76 | +129% |
| 2021 | $1.76 | $2.68 | +52% |
| 2022 | $2.68 | $1.09 | -59% |
| 2023 | $1.09 | $1.09 | 0% |
| 2024 | $1.09 | $0.50 | -54% |
| 2025 | $0.50 | $1.65 | +230% |
| 2026 YTD | $1.65 | $0.99 | -40% |
LCTX's yearly returns have swung widely, from +230% in 2025 to −59% in 2022. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LCTX on returns for 2026, with the stronger performance.